{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"25"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"25"}],"units":"Participants"}],"description":"Evidence of pharmacodynamic effect will be correlated with clinical response criteria. The pharmacodynamic effect of treatment is defined as the number of participants that had depletion DNMT1 with minimal DNA damage and cytotoxicity.","groups":[{"description":"INDUCTION PHASE: Patients receive decitabine subcutaneously (SQ) twice weekly for 4 weeks or thrice weekly until achieving bone marrow blasts \\< 5%. MAINTENANCE PHASE: Patients then receive decitabine SQ twice weekly for up to 52 weeks in the absence of disease progression or unacceptable toxicity.\n\nflow cytometry: Correlative studies\n\nDNA methylation analysis: Correlative studies\n\ncytogenetic analysis: Correlative studies\n\ndecitabine: Given subcutaneously\n\nmicroarray analysis: Correlative studies\n\ngene expression analysis: Correlative studies\n\npharmacological study: Correlative studies\n\npolymorphism analysis: Correlative studies","id":"OG000","title":"Arm I: Decitabine 0.2mg/kg"}],"paramType":"NUMBER","populationDescription":"All subjects that had treatment with DNMT1 depletion.","reportingStatus":"POSTED","timeFrame":"6 weeks after treatment","title":"Proportion of Patients With Pharmacodynamic Evidence of Drug Effect.","type":"SECONDARY","unitOfMeasure":"participants"}